<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698642</url>
  </required_header>
  <id_info>
    <org_study_id>CBL-16001(Phase 2a)</org_study_id>
    <nct_id>NCT04698642</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat</brief_title>
  <official_title>A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 2a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caliway Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caliway Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 2a component of the study will be a randomized, open-label, parallel, and multiple&#xD;
      dose study to further examine the safety and efficacy profile of 3 CBL-514 dose levels based&#xD;
      on the results from Phase 1 of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Actual">November 12, 2020</completion_date>
  <primary_completion_date type="Actual">November 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of abdominal subcutaneous fat volume</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Change of abdominal subcutaneous fat volume as measured by ultrasound around the treated area compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of abdominal subcutaneous fat thickness</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Change of abdominal subcutaneous fat thickness as measured by ultrasound-determined subcutaneous fat thickness over the treated area compared to Baseline,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Number of participants experiencing TEAEs and number of individual TEAEs among treatment groups by severity and relationship to investigational product (IP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Up to 4 weeks after last treatment</time_frame>
    <description>Clinical laboratory tests include Biochemistry, Hematology, Coagulation and Urinalysis test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in vital signs</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Vital signs measurements include temperature, pulse rate, blood pressure, and respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in Electrocardiogram (ECG)</measure>
    <time_frame>Up to 4 weeks after last treatment</time_frame>
    <description>ECG parameters include heart rate, RR interval, PR interval, QT interval, QTc interval, and QRS interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant abnormalities in physical examination</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Physical examinations include assessment of cardiovascular, respiratory, gastrointestinal, and neurological systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with injection site reactions</measure>
    <time_frame>Up to 8 weeks after last treatment</time_frame>
    <description>Injection site reactions include but not limited to redness, swelling, bruising, tenderness, itching, pain, warmth, discoloration and hardness</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Subcutaneous Fat</condition>
  <arm_group>
    <arm_group_label>CBL-514 180 mg, 1.2 mg/cm^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBL-514 will be administrated with the grid spacing of 2.5 cm^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBL-514 240 mg, 1.6 mg/cm^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBL-514 will be administrated with the grid spacing of 2.5 cm^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBL-514 300 mg, 2 mg/cm^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBL-514 will be administrated with the grid spacing of 2.5 cm^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBL-514</intervention_name>
    <description>Both sides of the abdominal region will receive CBL-514.</description>
    <arm_group_label>CBL-514 180 mg, 1.2 mg/cm^2</arm_group_label>
    <arm_group_label>CBL-514 240 mg, 1.6 mg/cm^2</arm_group_label>
    <arm_group_label>CBL-514 300 mg, 2 mg/cm^2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female aged 18 years to 64 years old (at Screening), inclusive.&#xD;
&#xD;
          2. Body mass index &gt;18.5 and &lt;35 kg/m2 and body weight ≥50 kg at Screening and Day 1.&#xD;
&#xD;
          3. Has WC between 80.0 cm and 110.0 cm at Screening and Day 1.&#xD;
&#xD;
          4. Subcutaneous fat thickness of at least 3.00 cm (30.0 mm) and up to 6.00 cm (60.0 mm)&#xD;
             by pinch method (measured by calibrated caliper) surrounding the center of treatment&#xD;
             area at Screening and Day 1.&#xD;
&#xD;
          5. Subject has stable body weight for at least 3 months before Screening and during the&#xD;
             study.&#xD;
&#xD;
          6. Subject who has maintained a stable lifestyle (e.g. exercise, eating patterns, and&#xD;
             smoking habit) for at least 3 months before Screening and during the study.&#xD;
&#xD;
          7. Voluntarily signs the Informed Consent Form and, in the opinion of the Investigator or&#xD;
             delegate, is physically and mentally capable of participating in the study, and&#xD;
             willing to adhere to study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subject of childbearing potential who is not willing to commit to an acceptable&#xD;
             contraceptive regimen with her partner from the time of Screening and throughout study&#xD;
             participation until 12 weeks after the last study drug dose, or who is currently&#xD;
             pregnant or lactating. Male subject who is not willing to commit to an acceptable&#xD;
             contraceptive method. For details on contraception, refer section 6.11.&#xD;
&#xD;
             Females who have been surgically sterilized (hysterectomy or bilateral oophorectomy)&#xD;
             or who are postmenopausal (e.g., defined as at least 50 years with ≥12 months of&#xD;
             amenorrhea with a follicle stimulating hormone &gt;40 IU/L) are considered to be of&#xD;
             non-childbearing potential. Subjects who are not of childbearing potential are not&#xD;
             required to use contraception.&#xD;
&#xD;
          2. Subject diagnosed with coagulation disorders or is receiving&#xD;
             anticoagulant/antiplatelet therapy or medications or dietary supplements, which impede&#xD;
             coagulation or platelet aggregation.&#xD;
&#xD;
          3. Subject has diabetes or glycated hemoglobin ≥6.5% (48 mmol/mol) or fasting blood sugar&#xD;
             ≥7 mmol/L.&#xD;
&#xD;
          4. Subject has a clinically significant cardiovascular disease and abnormal findings in&#xD;
             ECG.&#xD;
&#xD;
          5. Subject with active or prior history of malignancies (except for successfully treated&#xD;
             basal cell carcinoma) within 5 years before Screening or being worked-up for a&#xD;
             possible malignancy.&#xD;
&#xD;
          6. Subject with a history of human immunodeficiency virus (HIV)-1, hepatitis B, or&#xD;
             hepatitis C infections or subjects with active HIV, hepatitis B, or hepatitis C&#xD;
             infections at Screening:&#xD;
&#xD;
               1. Active HIV infection: positive HIV Ag/Ab combo test;&#xD;
&#xD;
               2. Active hepatitis B virus (HBV) infection: positive HBV surface antigen (HBsAg).&#xD;
                  Subjects with negative HBsAg but with positive HBV core antibody, with or without&#xD;
                  positive HBV surface antibody will also be excluded. However, subjects with&#xD;
                  negative HBsAg, negative HBV core antibody, and positive HBV surface antibody may&#xD;
                  be included.&#xD;
&#xD;
               3. Active hepatitis C virus (HCV) infection: positive HCV antibody.&#xD;
&#xD;
          7. Subject has abnormal skin or local skin conditions at the treatment area, which in the&#xD;
             opinion of Investigator is inappropriate to participate in the study, including but&#xD;
             not limited to any of the following:&#xD;
&#xD;
               1. Skin manifestations of a systemic disease,&#xD;
&#xD;
               2. Any abnormality of the skin or soft tissues of the abdominal wall in the area to&#xD;
                  be treated,&#xD;
&#xD;
               3. Skin or superficial tissue that does not lie flat on its own when the subject is&#xD;
                  in the supine position,&#xD;
&#xD;
               4. Sensory loss or dysesthesia in the area to be treated,&#xD;
&#xD;
               5. Evidence of any cause of enlargement in the abdominal area other than localized&#xD;
                  subcutaneous fat,&#xD;
&#xD;
               6. Tattoos on the area to be treated.&#xD;
&#xD;
          8. Subject who has hernia&#xD;
&#xD;
          9. Subject who has undergone the following procedures:&#xD;
&#xD;
               1. Previous open or laparoscopic abdominal surgery in the anticipated treatment&#xD;
                  area,&#xD;
&#xD;
               2. Cardiac pacemakers or any implantable electrical device,&#xD;
&#xD;
               3. Metal implants of any type in the area to be treated,&#xD;
&#xD;
               4. Esthetic procedure i.e. liposuction to the region to be treated within 12 months&#xD;
                  before Screening or during the study,&#xD;
&#xD;
               5. Esthetic procedure i.e. cryolipolysis, ultrasonic lipolysis, low level laser&#xD;
                  therapy , lipolysis injection to the region to be treated within 6 months before&#xD;
                  Screening or during the study.&#xD;
&#xD;
         10. Subject is on prescription or over-the-counter weight reduction medication or weight&#xD;
             reduction programs within 3 months before Screening or during the study.&#xD;
&#xD;
         11. Subject is undergoing chronic steroid or immunosuppressive therapy.&#xD;
&#xD;
         12. Requiring continual use of the following therapeutic agents during the study:1&#xD;
             S-mephenytoin (Mesantoin), terfenadine (Teldane), buspirone (Buspar), fexofenadine&#xD;
             (Fexotabs, Tefodine, Telfast, Xergic, Allegra).&#xD;
&#xD;
             If a subject needs to use the above mentioned therapeutic agents during the study for&#xD;
             any reason, these therapeutic agents should not be used at least for 2 days prior to&#xD;
             dosing until 1 day post-dose, whichever is later.&#xD;
&#xD;
         13. Unable to receive topical anesthesia (e.g., history of hypersensitivity to lidocaine).&#xD;
&#xD;
         14. Subjects with known allergies or sensitivities to the study drug and/or excipients&#xD;
&#xD;
         15. Subjects with inadequate liver function at Screening defined as aspartate&#xD;
             aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, or&#xD;
             gamma-glutamyl transferase &gt;3.0 × ULN.&#xD;
&#xD;
         16. Subjects with inadequate renal function, defined as abnormal serum creatinine, and&#xD;
             urea &gt;1.5 × ULN or estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m2.&#xD;
             Subjects who are currently on dialysis should be excluded.&#xD;
&#xD;
         17. Use of other investigational drug or device within 4 weeks prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

